JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr

JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market

Lupin acquires five brands from Menarini

Lupin has been exclusively marketing these brands in the Indian market since July 2021

Briefs: Concord Biotech, Cian Healthcare and Eris Lifesciences

Eris Lifesciences enters into term loan agreement with Citi Bank

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Granules India announces approval for Acetaminophen and Ibuprofen Tablets

This product will be launched through Granules Consumer Health (GCH) division

InnoCan submits new patent applications for advanced pain relief technology

The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution

Agilent to appeal patent office decision on CRISPR gRNA patents

Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.

Microbion gets US patent for the use of inhaled pravibismane for pulmonary infections

Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039